Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Rockwell Medical appoints Heather Hunter as chief corporate affairs officer » 08:16
09/07/22
09/07
08:16
09/07/22
08:16
RMTI

Rockwell Medical

$1.56 /

-0.075 (-4.59%)

Rockwell Medical…

Rockwell Medical announced that Heather Hunter has joined the company as SVP, chief corporate affairs officer. In this role, Hunter will be responsible for the company's investor relations, media relations, government affairs, patient advocacy, communications, and branding. Prior to joining Rockwell, Hunter led communications at Venatorx Pharmaceuticals, a private, pre-commercial anti-infectives pharmaceutical company.

ShowHide Related Items >><<
RMTI Rockwell Medical
$1.56 /

-0.075 (-4.59%)

RMTI Rockwell Medical
$1.56 /

-0.075 (-4.59%)

08/30/22 H.C. Wainwright
Rockwell Medical price target raised to $8 from $3 at H.C. Wainwright
01/18/22 H.C. Wainwright
Rockwell Medical price target lowered to $3 from $5 at H.C. Wainwright
RMTI Rockwell Medical
$1.56 /

-0.075 (-4.59%)

Over a month ago
Recommendations
Rockwell Medical price target raised to $8 from $3 at H.C. Wainwright » 06:07
08/30/22
08/30
06:07
08/30/22
06:07
RMTI

Rockwell Medical

$1.42 /

-0.02 (-1.39%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Rockwell Medical to $8 from $3 and keeps a Buy rating on the shares. The analyst increased the target to reflect the impact of reverse split and focus on the dialysates business.

ShowHide Related Items >><<
RMTI Rockwell Medical
$1.42 /

-0.02 (-1.39%)

RMTI Rockwell Medical
$1.42 /

-0.02 (-1.39%)

01/18/22 H.C. Wainwright
Rockwell Medical price target lowered to $3 from $5 at H.C. Wainwright
RMTI Rockwell Medical
$1.42 /

-0.02 (-1.39%)

Syndicate
Rockwell Medical files to sell 1.4M shares of common stock for holders  17:26
07/14/22
07/14
17:26
07/14/22
17:26
RMTI

Rockwell Medical

$1.26 /

-0.03 (-2.33%)

 
ShowHide Related Items >><<
RMTI Rockwell Medical
$1.26 /

-0.03 (-2.33%)

RMTI Rockwell Medical
$1.26 /

-0.03 (-2.33%)

01/18/22 H.C. Wainwright
Rockwell Medical price target lowered to $3 from $5 at H.C. Wainwright
RMTI Rockwell Medical
$1.26 /

-0.03 (-2.33%)

Over a quarter ago
Hot Stocks
Rockwell Medical CEO Russell Ellison to step down, Mark Strobeck to succeed » 08:58
06/24/22
06/24
08:58
06/24/22
08:58
RMTI

Rockwell Medical

$1.37 /

+0.09 (+7.03%)

Rockwell Medical…

Rockwell Medical announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and CEO, effective July 1. Dr. Strobeck will also join the company's Board of Directors. Russell Ellison, M.D., M.Sc., will be stepping down as President and CEO and as a member of the company's Board of Directors effective June 30. Mark Strobeck, Ph.D. brings 20+ years of operating, business development, capital raising and investing experience in life sciences for both private and public biotechnology companies. Prior to joining Rockwell Medical, Mark was a Managing Partner at Aquilo Partners, a life science investment banking firm specializing in mergers and acquisitions and strategic partnering transactions.

ShowHide Related Items >><<
RMTI Rockwell Medical
$1.37 /

+0.09 (+7.03%)

RMTI Rockwell Medical
$1.37 /

+0.09 (+7.03%)

01/18/22 H.C. Wainwright
Rockwell Medical price target lowered to $3 from $5 at H.C. Wainwright
RMTI Rockwell Medical
$1.37 /

+0.09 (+7.03%)

On The Fly
Fly Intel: After-Hours Movers » 17:57
06/22/22
06/22
17:57
06/22/22
17:57
SCS

Steelcase

$10.44 /

+0.02 (+0.19%)

, WOR

Worthington

$40.40 /

-0.56 (-1.37%)

, KBH

KB Home

$26.22 /

+0.62 (+2.42%)

, FUL

H.B. Fuller

$61.45 /

+0.08 (+0.13%)

, APLT

Applied Therapeutics

$1.07 /

-0.01 (-0.93%)

, RMTI

Rockwell Medical

$1.28 /

-0.02 (-1.54%)

, XENE

Xenon Pharmaceuticals

$34.68 /

+1.84 (+5.60%)

Check out this evening's…

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$34.68 /

+1.84 (+5.60%)

WOR Worthington
$40.40 /

-0.56 (-1.37%)

SCS Steelcase
$10.44 /

+0.02 (+0.19%)

RMTI Rockwell Medical
$1.28 /

-0.02 (-1.54%)

KBH KB Home
$26.22 /

+0.62 (+2.42%)

FUL H.B. Fuller
$61.45 /

+0.08 (+0.13%)

APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

SCS Steelcase
$10.44 /

+0.02 (+0.19%)

WOR Worthington
$40.40 /

-0.56 (-1.37%)

08/23/21 Seaport Global
Worthington initiated with a Neutral at Seaport Global
KBH KB Home
$26.22 /

+0.62 (+2.42%)

06/16/22 UBS
KB Home price target lowered to $45 from $66 at UBS
06/08/22 Barclays
KB Home price target lowered to $44 from $47 at Barclays
05/13/22 Wolfe Research
KB Home downgraded to Underperform from Peer Perform at Wolfe Research
04/13/22 JPMorgan
KB Home price target lowered to $39 from $49 at JPMorgan
FUL H.B. Fuller
$61.45 /

+0.08 (+0.13%)

04/18/22 Deutsche Bank
H.B. Fuller upgraded on 'significant valuation upside' at Deutsche Bank
04/18/22 Deutsche Bank
H.B. Fuller upgraded to Buy from Hold at Deutsche Bank
04/14/22 Baird
H.B. Fuller upgraded to Outperform at Baird after underperformance
04/14/22 Baird
H.B. Fuller upgraded to Outperform from Neutral at Baird
APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

04/13/22 Truist
Applied Therapeutics price target lowered to $6 from $85 at Truist
03/21/22 Barclays
Applied Therapeutics price target lowered to $2.50 from $7 at Barclays
01/05/22 Citi
Applied Therapeutics price target lowered to $30 from $38 at Citi
01/04/22 Goldman Sachs
Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs
RMTI Rockwell Medical
$1.28 /

-0.02 (-1.54%)

01/18/22 H.C. Wainwright
Rockwell Medical price target lowered to $3 from $5 at H.C. Wainwright
XENE Xenon Pharmaceuticals
$34.68 /

+1.84 (+5.60%)

11/11/21 SVB Securities
Xenon Pharmaceuticals price target raised to $40 from $34 at SVB Leerink
10/28/21 RBC Capital
Xenon Pharmaceuticals initiated with an Outperform at RBC Capital
10/06/21 Wedbush
Wedbush remains bullish on Xenon as financing gives firepower to advance XEN1101
10/04/21 Jefferies
Jefferies ups Xenon target to $50 after 'home run' epilepsy data
XENE Xenon Pharmaceuticals
$34.68 /

+1.84 (+5.60%)

WOR Worthington
$40.40 /

-0.56 (-1.37%)

SCS Steelcase
$10.44 /

+0.02 (+0.19%)

KBH KB Home
$26.22 /

+0.62 (+2.42%)

FUL H.B. Fuller
$61.45 /

+0.08 (+0.13%)

APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

  • 23
    Jun
  • 06
    Oct
KBH KB Home
$26.22 /

+0.62 (+2.42%)

APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

WOR Worthington
$40.40 /

-0.56 (-1.37%)

SCS Steelcase
$10.44 /

+0.02 (+0.19%)

KBH KB Home
$26.22 /

+0.62 (+2.42%)

FUL H.B. Fuller
$61.45 /

+0.08 (+0.13%)

APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

KBH KB Home
$26.22 /

+0.62 (+2.42%)

FUL H.B. Fuller
$61.45 /

+0.08 (+0.13%)

Syndicate
Rockwell Medical files to sell 11.17M shares of common stock for holders  16:12
06/22/22
06/22
16:12
06/22/22
16:12
RMTI

Rockwell Medical

$1.29 /

-0.01 (-0.77%)

 
ShowHide Related Items >><<
RMTI Rockwell Medical
$1.29 /

-0.01 (-0.77%)

RMTI Rockwell Medical
$1.29 /

-0.01 (-0.77%)

01/18/22 H.C. Wainwright
Rockwell Medical price target lowered to $3 from $5 at H.C. Wainwright
Hot Stocks
Rockwell Medical receives second $7.5M investment from DaVita » 16:07
06/22/22
06/22
16:07
06/22/22
16:07
RMTI

Rockwell Medical

$1.29 /

-0.01 (-0.77%)

, DVA

DaVita

$80.57 /

+4.5 (+5.92%)

Rockwell Medical (RMTI)…

Rockwell Medical (RMTI) provided an update on its recent capital raise and a clinical update on safety enhancements to its planned Phase 2 clinical trial of Ferric Pyrophosphate Citrate in home infusion patients. On June 16, Rockwell Medical closed the second $7.5M tranche of the DaVita (DVA) stock purchase agreement under which DaVita agreed to purchase up to $15M in convertible preferred stock in two tranches. This investment, in addition to the recent $15M financing, brings the total gross amount raised by Rockwell this quarter to $30M. There were no commissions paid on either investment. The planned Phase 2 proof of concept study design requires that three units of the existing FDA-approved IV product be compounded into a single unit for each patient dose. Because of this necessary step, the FDA requested that Rockwell perform a microbial challenge study, a standard study testing the potential for microbial growth.

ShowHide Related Items >><<
RMTI Rockwell Medical
$1.29 /

-0.01 (-0.77%)

DVA DaVita
$80.57 /

+4.5 (+5.92%)

RMTI Rockwell Medical
$1.29 /

-0.01 (-0.77%)

01/18/22 H.C. Wainwright
Rockwell Medical price target lowered to $3 from $5 at H.C. Wainwright
DVA DaVita
$80.57 /

+4.5 (+5.92%)

06/22/22 Truist
Fresenius Medical price target lowered to $27 from $34 at Truist
06/22/22 Truist
DaVita price target lowered to $90 from $110 at Truist
06/21/22 Barclays
DaVita faces risk of multi-year overhang after SCOTUS ruling, says Barclays
05/06/22 Truist
DaVita price target lowered to $110 from $125 at Truist
DVA DaVita
$80.57 /

+4.5 (+5.92%)

DVA DaVita
$80.57 /

+4.5 (+5.92%)

DVA DaVita
$80.57 /

+4.5 (+5.92%)

Hot Stocks
Rockwell Medical names Mark Strobeck, Ph.D., as CEO, succeeding Russell Ellison » 08:02
06/22/22
06/22
08:02
06/22/22
08:02
RMTI

Rockwell Medical

$1.35 /

+0.02 (+1.50%)

Rockwell Medical…

Rockwell Medical announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and CEO, effective July 1. Dr. Strobeck will also join the company's Board of Directors. Russell Ellison, M.D., M.Sc., will be stepping down as President and CEO and as a member of the company's Board of Directors effective June 30. Mark Strobeck, Ph.D. brings 20+ years of operating, business development, capital raising and investing experience in life sciences for both private and public biotechnology companies. Prior to joining Rockwell Medical, Mark was a Managing Partner at Aquilo Partners, a life science investment banking firm specializing in mergers and acquisitions and strategic partnering transactions

ShowHide Related Items >><<
RMTI Rockwell Medical
$1.35 /

+0.02 (+1.50%)

RMTI Rockwell Medical
$1.35 /

+0.02 (+1.50%)

01/18/22 H.C. Wainwright
Rockwell Medical price target lowered to $3 from $5 at H.C. Wainwright
Syndicate
Rockwell Medical announces $15M at-the-market offering » 08:06
05/31/22
05/31
08:06
05/31/22
08:06
RMTI

Rockwell Medical

$1.37 /

-0.17 (-11.04%)

, DVA

DaVita

$97.77 /

+0.35 (+0.36%)

Rockwell Medical (RMTI)…

Rockwell Medical (RMTI) "announced that it has entered into securities purchase agreements with Armistice Capital Master Fund Ltd., a leading healthcare investor, to purchase $15M of common stock and warrants. The combined purchase price for one share of common stock (or common stock equivalent) and a warrant to purchase one share of common stock is $1.515. The warrants have an exercise price of $1.39 per share and have a term of 5.5 years. The receipt of the $15M in proceeds is expected to trigger a subsequent $7.5M investment from DaVita, Inc (DVA). on terms previously disclosed. The company intends to use the net proceeds to restructure its dialysis business and, pending FDA clearance, to advance the development of ferric pyrophosphate citrate for patients with iron deficiency anemia who are receiving home infusion therapy."

ShowHide Related Items >><<
RMTI Rockwell Medical
$1.37 /

-0.17 (-11.04%)

DVA DaVita
$97.77 /

+0.35 (+0.36%)

RMTI Rockwell Medical
$1.37 /

-0.17 (-11.04%)

01/18/22 H.C. Wainwright
Rockwell Medical price target lowered to $3 from $5 at H.C. Wainwright
DVA DaVita
$97.77 /

+0.35 (+0.36%)

05/06/22 Truist
DaVita price target lowered to $110 from $125 at Truist
01/05/22 Truist
DaVita price target raised to $125 from $114 at Truist
11/17/21 Deutsche Bank
DaVita price target lowered to $150 from $164 at Deutsche Bank
10/29/21 Deutsche Bank
DaVita price target lowered to $164 from $207 at Deutsche Bank
DVA DaVita
$97.77 /

+0.35 (+0.36%)

DVA DaVita
$97.77 /

+0.35 (+0.36%)

Hot Stocks
Rockwell Medical submits additional home infusion IND application data to FDA » 08:15
05/12/22
05/12
08:15
05/12/22
08:15
RMTI

Rockwell Medical

/

+

Rockwell Medical provided…

Rockwell Medical provided the FDA with the supplemental data, requested by the agency in December 2021, for the company's pending Investigational New Drug application in support of a proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate - FPC - for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting. The additional data relate to the physical, chemical and microbiological stability of FPC in support of the suggested method of administration in the Phase 2 protocol. The FDA has 30 days to review the additional data that have been submitted. In the event that the FDA has no further questions or requirements regarding the submission, the company would expect the trial to start shortly after the review period ends.

ShowHide Related Items >><<
RMTI Rockwell Medical
/

+

RMTI Rockwell Medical
/

+

01/18/22 H.C. Wainwright
Rockwell Medical price target lowered to $3 from $5 at H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.